Ionis Pharmaceuticals

Traded on the St. Petersburg Stock Exchange
Ionis Pharmaceuticals is a biotechnology company based in Carlsbad, California that specializes in discovering and developing RNA-targeted therapeutics. The company has 3 commercially approved medicines: Spinraza, Tegsedi, and WAYLIVRA. The company was founded in 1989 as Isis Pharmaceuticals by Stanley T. Crooke, a former head of research of GlaxoSmithKline, with a goal to commercialize antisense therapy. In December 2015, Isis changed its name to Ionis.
Ionis Pharmaceuticals stock price chart
vol.
change
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Ionis Pharmaceuticals balance sheet

Report period2017 2018 2019 2020 2021 2022
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Ionis Pharmaceuticals cash flows

Report period2017 2018 2019 2020 2021 2022
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Ionis Pharmaceuticals multipliers

Report period2017 2018 2019 2020 2021 2022
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Ionis Pharmaceuticals profitability

Report period2017 2018 2019 2020 2021 2022
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Ionis Pharmaceuticals assets
Ionis Pharmaceuticals cash flows

Ionis Pharmaceuticals shares

TickerNameTypeNominal valueISINPrice
IONS:USIonis Pharmaceuticals, Inc.Common share-US4622221004$46.92
Ionis Pharmaceuticals news
13.06.2022
FDA has granted orphan drug status to Ionis Pharmaceuticals' ION582 for the treatment of Angelman syndrome in children. The drug is still in Phase 1/2 clinical trials, which are expected to be completed in 2023.
Source: ir.ionispharma.com pictogram ir.ionispharma.com
Pictogram next
04.05.2022
Ionis Pharmaceuticals' GAAP loss for 3 months of 2022 was $65 million, down 27.8% from $90 million in the previous year. Revenues increased 26.8% to $142 million from $112 million a year earlier.
Source: ir.ionispharma.com pictogram ir.ionispharma.com
Pictogram next
24.02.2022
Ionis Pharmaceuticals' GAAP loss for 2021 was $29 million, down 16.6 times from $480 million in the previous year. Revenue increased 11.1% to $810 million from $729 million a year earlier.
Source: ir.ionispharma.com pictogram ir.ionispharma.com
Pictogram next
31.01.2022
Pfizer and Ionis Pharmaceuticals are discontinuing a joint study of the candidate drug vupanorsen. The drug was being developed as a drug to reduce the risk of cardiovascular disease and severe hypertriglyceridemia. Pfizer will return the development rights to Ionis.
Source: ir.ionispharma.com pictogram ir.ionispharma.com
Pictogram next
All Ionis Pharmaceuticals news
General information
Company nameIonis Pharmaceuticals
Tags#biotechnology
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology
Business address2855 GAZELLE COURT CARLSBAD CA 92010 7609319200
Mailing address2855 GAZELLE COURT CARLSBAD CA 92010
Websitewww.ionispharma.com
Information disclosurewww.sec.gov